The average progression rate from one stage of liver fibrosis to the next in humans with NASH is estimated to be seven years, compared to 14 years with<unk> . The course of progression varies with different clinical manifestations among individuals. Fibrosis in humans with NASH progressed more rapidly than in humans with<unk> . Obesity predicts a worse long-term outcome than for lean individuals. In the Asia-Pacific region, about 25% of<unk>  cases progress to NASH under three years, but only a low proportion (3.7%) develop advanced liver fibrosis. An international study showed that people with<unk>  had a 10-year survival rate of 81.5%.<unk>  is a risk factor for fibrosis, hypertension, chronic kidney disease, atrial fibrillation, myocardial infarction, ischemic stroke, and death from cardiovascular causes based on very-low to low-quality evidence from observational studies. Although<unk>  can cause cirrhosis and liver failure and liver cancer, most deaths among people with<unk>  are attributable to cardiovascular disease. According to a meta-analysis of 34,000 people with<unk>  over seven years, these individuals have a 65% increased risk of developing fatal or<unk> fatal cardiovascular events when compared to those without<unk> .<unk>  and NASH increase the risk of liver cancer. Cirrhosis and liver cancer induced by<unk>  were the second cause of liver transplantation in the US in 2017. Liver cancer develops in NASH in the absence of cirrhosis in 45% in the cases, and people with NASH cirrhosis have an increased risk of liver cancer. The rate of liver cancer associated with NASH increased fourfold between 2002 and 2012 in the US, which is more than any other cause of liver cancer.<unk>  constitutes the third most common risk factor for liver cancer.<unk>  and NASH were found to worsen with cirrhosis in respectively 2–3% and 15–20% of the people over a 10–20 year period. Cirrhosis is found in only about 50% of people with<unk>  and with liver cancer, so that liver cancer and cirrhosis are not always linked.<unk>  may be a precursor of metabolic syndrome, although a bidirectional influence is possible. The presence and stage of fibrosis are the strongest prognostic factors for liver-related events and mortality, in particular for<unk> .
Non-alcoholic fatty liver disease
Metabolic syndrome
Alcoholic liver disease
Alcoholic hepatitis
Fatty liver disease
Autoimmune hepatitis
Viral hepatitis
Polycystic liver disease